CN116711781A - Application of composition in preparation of product for improving intestinal development - Google Patents

Application of composition in preparation of product for improving intestinal development Download PDF

Info

Publication number
CN116711781A
CN116711781A CN202310814187.8A CN202310814187A CN116711781A CN 116711781 A CN116711781 A CN 116711781A CN 202310814187 A CN202310814187 A CN 202310814187A CN 116711781 A CN116711781 A CN 116711781A
Authority
CN
China
Prior art keywords
whey protein
content
parts
weight
protein powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310814187.8A
Other languages
Chinese (zh)
Inventor
安晓楠
刘宾
孔小宇
刘彪
李婷
司徒文佑
段素芳
闫雅璐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Priority to CN202310814187.8A priority Critical patent/CN116711781A/en
Publication of CN116711781A publication Critical patent/CN116711781A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/06—Mixtures of whey with milk products or milk components
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C13/00—Cream; Cream preparations; Making thereof
    • A23C13/12—Cream preparations
    • A23C13/14—Cream preparations containing milk products or non-fat milk components
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
    • A23C19/0917—Addition, to cheese or curd, of whey, whey components, substances recovered from separated whey, isolated or concentrated proteins from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/005—Condensed milk; Sugared condensed milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/18—Milk in dried and compressed or semi-solid form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206—Colostrum; Human milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/40—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds characterised by the dairy products used
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dairy Products (AREA)

Abstract

The application provides an application of a composition in preparing a product for improving intestinal development; the composition comprises 1-10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide. The mass ratio provided by the application is (1-10): 1 the composition of the whey protein powder rich in milk fat globule membrane and the whey protein powder rich in casein glycomacropeptide has a synergistic effect on promoting intestinal development, and can remarkably improve the villus height and the intestinal villus crypt ratio of intestinal tracts.

Description

Application of composition in preparation of product for improving intestinal development
Technical Field
The application relates to the technical field of foods, in particular to application of a composition in preparation of a product for improving intestinal development.
Background
The phospholipid is used as a milk fat, can promote the absorption and transportation of fat digestion products in the digestive tract, and also participates in the functions of body immunoregulation, nerve signal transmission and the like, and promotes the development and maturation of the brain. Phospholipids in milk are found in two structures: milk Fat Globule Membrane (MFGM) and exosomes (nanovesicles), most phospholipids are present in the milk fat globule membrane (60% -70%). The milk fat globule membrane is a three-layer membrane structure which wraps the fat globules and has the function of preventing the fat globules from gathering, so that the fat globules are emulsified and dispersed in milk. Milk fat globule membranes contain in addition to phospholipids, in excess of 200 proteins, cholesterol, enzymes and other minor components, which are currently monitored mainly by phospholipid concentration and the presence of membrane proteins due to their complex variability in composition and structure. MFGM is mainly composed of a variety of active lipids and proteins, and is derived from the endoplasmic reticulum membrane, apical plasma membrane and cytoplasmic compartments of mammary epithelial cells in lactation, accounting for 2% -6% of the mass of milk fat globules. Lipid components on MFGM are largely divided into neutral lipids and polar lipids. Polar lipids account for 26% -40% of MFGM lipid components, including glycerophospholipids [ Phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS) and Phosphatidylinositol (PI) ] and sphingolipids [ in particular Sphingomyelin (SM) ]. Wherein, PE, PC, SM content is more abundant, and PS and PI content is less. The polar lipids mainly have the functions of regulating lipid metabolism, participating in nervous system activities and the like. Neutral lipids include triglycerides, sterols and sterol esters (mainly cholesterol), glycosphingolipids (cerebrosides and gangliosides), and also diglycerides, monoglycerides, free fatty acids, etc. Wherein, the triglyceride accounts for 56% -62% of the lipid component of the MFGM, and is a non-membrane lipid component of the MFGM in the separation and purification process.
Sialic acid is generally located at the end of macromolecules such as glycoproteins and glycolipids and is an important component of glycoproteins and glycolipids on cell membranes. The human milk contains 0.3-1.5mg/ml sialic acid, and exists mainly in a combined state, and comprises human milk oligosaccharide, glycolipid and glycoprotein, wherein the human milk oligosaccharide is taken as a main form and accounts for 75% of total sialic acid in human milk. Sialic acids have a variety of biological functions: proliferation, differentiation and recognition of cells; interaction with pathogenic microorganisms, participating in an immune response; promoting development of nervous system, facilitating formation of memory, and improving learning ability.
In the prior art, the effect of the milk fat globule membrane and casein glycomacropeptide on intestinal development is not clear, and further research is needed.
At present, in the fields of infant formulas, children foods, complementary foods and nutritional supplements, solutions for relieving intestinal discomfort and improving intestinal development are needed.
Disclosure of Invention
In view of the above, the present application aims to provide a composition for improving intestinal development.
The application of the composition provided by the application in preparing a product for improving intestinal development; the composition comprises 1-10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
Preferably, the composition comprises 5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
Preferably, the content of phospholipids in the whey protein powder rich in the milk fat globule membrane is not less than 4wt%; the content of sialic acid in the whey protein powder rich in casein glycomacropeptide is not less than 3wt%.
Preferably, the product comprises an infant formula and/or a child formula.
Preferably, the infant formula contains 8-20 g/100g of total protein and 40-80% of whey protein in terms of dry matter; the fat content is 15 g-30 g/100g; the carbohydrate content is 50 g-70 g/100g;
the linoleic acid content is 2700-4500 mg/100g, and the alpha-linolenic acid content is 270-450 mg/100g.
Preferably, the infant formula further comprises one or more of nutrients, dietary fibers, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, lactoferrin, OPO, casein calcium peptide or casein phosphopeptide.
Preferably, the children's formula has a total protein content of greater than 16.5g/100g in reduced dry matter;
the children formula food also comprises one or more of nutrients, dietary fibers, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotide, lactoferrin, OPO, casein calcium peptide or casein phosphopeptide.
Preferably, the improving intestinal development comprises increasing intestinal villus height and/or increasing crypt depth.
Preferably, the improving intestinal development comprises increasing the chorionic villus ratio.
Preferably, the intestinal tract is the jejunum and/or ileum.
Compared with the prior art, the application provides the application of the composition in preparing the product for improving the intestinal development; the composition comprises 1-10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide. The mass ratio provided by the application is (1-10): 1 the composition of the whey protein powder rich in milk fat globule membrane and the whey protein powder rich in casein glycomacropeptide has a synergistic effect on promoting intestinal development, and can remarkably improve the villus height and the intestinal villus crypt ratio of intestinal tracts.
Drawings
FIG. 1 shows the weight change of piglets;
FIG. 2 is a graph showing the weight gain of piglets;
FIG. 3 is a graph of piglet feed intake results;
FIG. 4 is a graph showing the total weight and length results of the small intestine;
FIG. 5 is a graph of small intestine length versus weight results for each group;
FIG. 6 is a graph of results of villus length and crypt depth for duodenum, jejunum and ileum;
FIG. 7 is a graph of results of villus length, crypt depth, and villus crypt ratio of the small intestine;
FIG. 8 is a graph of results of jejunum villus length, crypt depth, and villus crypt ratio;
fig. 9 is a graph of results of villus length, crypt depth, and villus cryptoratio of the ileum.
Detailed Description
The application provides the application of the composition in preparing products for improving intestinal development, and one skilled in the art can realize the appropriate improvement of process parameters by referring to the content of the application. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present application. While the methods and applications of this application have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that the application can be practiced and practiced with modification and alteration and combination of the methods and applications herein without departing from the spirit and scope of the application.
In the present application, the term "and/or" describes an association relationship of an association object, which means that three relationships may exist, for example, a and/or B may mean that a exists alone, a and B exist together, and B exists alone. Wherein A, B may be singular or plural.
In the present application, "at least one" means one or more; "plurality of" means two or more. "at least one of" or the like means any combination of these items, including any combination of single item(s) or plural items(s).
It should be understood that, in various embodiments of the present application, the sequence number of each process described above does not mean that the execution sequence of some or all of the steps may be executed in parallel or executed sequentially, and the execution sequence of each process should be determined by its functions and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
The application of the composition provided by the application in preparing a product for improving intestinal development; the composition comprises 1-10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
In a preferred embodiment of a part of the present application, the composition comprises 1 to 8 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
In a preferred embodiment of a part of the present application, the composition comprises 2.5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
In a preferred embodiment of a part of the present application, the composition comprises 3.5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
In a preferred embodiment of a part of the present application, the composition comprises 4.5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
In a preferred embodiment of a part of the present application, the composition comprises 5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
The application creatively discovers that the whey protein powder containing the milk fat globule membrane and the whey protein powder rich in casein glycomacropeptide in the proportion can improve intestinal development.
The products of the present application include infant formulas and/or children formulas.
The food product according to the application preferably comprises a dairy product.
The dairy product comprises liquid milk (pasteurized milk, sterilized milk, prepared milk, fermented milk); milk powder (whole milk powder, skim milk powder, partially skim milk powder, modified milk powder, bovine colostrum powder); other dairy products. The method specifically comprises the following steps: the first is liquid milk. Mainly comprises sterilized milk, yoghourt and the like. The second category is the milk powder category. Including whole milk powder, skim milk powder, whole sweetened milk powder, flavored milk powder, infant milk powder, and other formula milk powders. The third class is condensed milk. The fourth group is the milk fat group. Including cream for cake making, common breaded butter, and the like. The fifth category is cheeses. The sixth category is the cream category. The seventh category is other dairy products. Mainly comprises casein, lactose, milk slices and the like.
The dairy product according to the application preferably comprises one or more of modified milk, modified milk powder, fermented milk, milk flakes, cheese or milk-based snack products.
According to the specific embodiment of the application, the infant formula of the application has a total protein content of 8 g-20 g/100g and whey protein accounting for 40% -70% of the total protein; the fat content is 15 g-30 g/100g; the carbohydrate content is 50 g-70 g/100g; preferably, the infant formula has a total protein content of 10 g-18 g/100g in reduced dry matter; whey protein accounts for 40% -65% of total protein; the fat content is 18 g-28 g/100g; the carbohydrate content is 52 g-60 g/100g. .
According to a specific embodiment of the application, the infant formula of the application also contains linoleic acid and alpha-linolenic acid, wherein the linoleic acid content is 2700-4500 mg/100g, and the alpha-linolenic acid content is 270-450 mg/100g.
According to a specific embodiment of the present application, the infant formula in the present application may be a formula for infants from 0 to 6 months, a formula for older infants from 6 to 12 months or a formula for infants from 12 to 36 months.
Specifically, the formula for 0-6 month infants is reduced to dry matters, the total protein content is 8-15 g/100g, the whey protein accounts for 60-70% of the total protein, the fat content is 23-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-60 g/100g.
The formula food for older infants of 6-12 months age has the total protein content of 8-20 g/100g, the whey protein content of 40-70% of the total protein, the fat content of 20-30 g/100g, the linoleic acid content of 2700-4500 mg/100g, the alpha-linolenic acid content of 270-450 mg/100g and the carbohydrate content of 50-60 g/100g.
The formula food for infants of 12-36 months is reduced to dry matters, the total protein content is 8-20 g/100g, the fat content is 20-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-60 g/100g.
According to a specific embodiment of the present application, in the infant formula of the present application, the raw materials for providing total protein include: raw milk (cattle/sheep), whole milk powder (cattle/sheep), skimmed milk powder (cattle/sheep), whey protein powder (cattle/sheep), desalted whey powder (cattle/sheep), and beta-casein. Specifically, based on 1000 parts by weight of the infant formula, the infant formula comprises the following raw materials: raw milk (cattle/sheep) 0-3500 parts, whole milk powder 0-260 parts (cattle/sheep), whey protein powder (cattle/sheep) 0-120 parts, skim milk powder (cattle/sheep) 0-400 parts, and/or desalted whey powder (cattle/sheep) 0-600 parts, with the addition of beta-casein being 0-40 parts.
According to a specific embodiment of the application, in the infant formula of the application, the raw materials for providing fat comprise one or more of the following raw materials in parts by weight: 0-50 parts of corn oil, 0-65 parts of soybean oil, 0-100 parts of sunflower seed oil, 0-240 parts of 1, 3-dioleoyl-2-palmitic acid triglyceride, 0-30 parts of coconut oil, 0-85 parts of canola oil and 0-20 parts of linseed oil.
According to a specific embodiment of the present application, the infant formula of the present application, wherein the carbohydrate-providing raw materials comprise: lactose 0-500 parts, and/or the above protein material containing lactose.
According to a specific embodiment of the present application, the infant formula of the present application may comprise, in addition to the above components, conventional components of infant formulas, for example, one or more of nutrients, dietary fibers, inositol, taurine, L-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, lactoferrin. Preferably comprising a reconstituted nutrient package. In some preferred embodiments, the infant formula comprises 0-20 parts of nutrients including vitamins and minerals, or further optionally one or more of dietary fiber (fructooligosaccharides, galactooligosaccharides, polyfructose, etc.), inositol, taurine, l-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, lactoferrin, probiotics. The compound nutrient mainly comprises the following components: and (3) compounding vitamins: vitamin A, vitamin D, vitamin E, vitamin K 1 Vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 One or more of niacin, folic acid, pantothenic acid, vitamin C, choline, biotin; compounding minerals: sodium, potassium, calcium, phosphorus, copper, iron, zinc, manganese, iodine, selenium, magnesium, potassium, and derivatives thereof. The sources, the contents and the usage amount of each vitamin and mineral are in accordance with the national standard and related regulations of infant formula food.
The children's formula of the present application has a total protein content of more than 16.5g/100g in reduced dry matter. According to a specific embodiment of the present application, in the child formula of the present application, the raw materials for providing total protein include: raw milk (cattle/sheep), whole milk powder (cattle/sheep), skimmed milk powder (cattle/sheep), whey protein powder (cattle/sheep), desalted whey powder (cattle/sheep), and beta-casein. Specifically, based on 1000 parts by weight of the infant formula, the infant formula comprises the following raw materials: raw milk (cattle/sheep) 0-3500 parts, whole milk powder 0-260 parts (cattle/sheep), whey protein powder (cattle/sheep) 0-120 parts, skim milk powder (cattle/sheep) 0-400 parts, and/or desalted whey powder (cattle/sheep) 0-600 parts, with the addition of beta-casein being 0-40 parts.
Wherein the children formula food also comprises one or more of nutrients, dietary fibers, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotide, lactoferrin, OPO, casein calcium peptide and casein phosphopeptide.
According to a specific embodiment of the present application, the present application is applied in the preparation of a milk fat globule membrane and casein glycomacropeptide composition for pediatric formulas, wherein the milk fat globule membrane and casein glycomacropeptide are provided by whey protein powder, and the content of phospholipids in the whey protein powder (milk fat globule enriched membrane) is not less than 4wt%. The content of sialic acid in the whey protein powder (rich in casein glycomacropeptide) is not less than 3wt%.
The application provides an improved intestinal development, which comprises the steps of increasing intestinal villus height and/or increasing crypt depth.
The improvement of intestinal development according to the application comprises an increase in the chorionic villus ratio.
The intestinal tract of the application is jejunum and/or ileum.
According to a specific embodiment of the present application, the pediatric formula of the present application has the effect of promoting intestinal development.
According to a specific embodiment of the application, the organism comprises an animal or a human in the use of the composition of the application.
The infant formula of the application has the effect of promoting intestinal development due to the composition comprising the milk fat globule membrane and casein glycomacropeptide.
In another aspect, the application also provides a method for preparing the pediatric formula, which comprises the step of mixing the milk fat globule membrane and the casein glycomacropeptide composition with other raw materials in the formula by adopting a wet or dry production process to prepare the formula. The preparation process mainly comprises the following steps: proportioning, homogenizing, concentrating, sterilizing, spray drying and dry mixing to obtain the finished product. In the application, the milk fat globule membrane and the casein glycomacropeptide can be mixed together in the process of mixing, and can also be added in the process of post-mixing.
In summary, the application finds that the composition comprising milk fat globule membrane and casein glycomacropeptide has the effect of promoting intestinal development, can improve intestinal villus height and/or intestinal villus crypt ratio, and has wide application prospect when being applied to infant formulas.
The application is further illustrated by the following examples:
example 1
The present example provides a powdered infant formula of 0 to 6 months of age having a total protein content of 10.7g/100g powder and a fat content of 27.9g/100g powder; a carbohydrate content of 55.2g/100g flour; probiotics 1×10 8 CFU/100g powder; milk fat globule membrane: casein glycomacropeptide = 9:1.
the embodiment is realized by compounding the following raw materials in parts by weight:
1000 parts of raw milk, 77 parts of lactose, 120 parts of mixed vegetable oil, 110 parts of OPO structural grease, 485 parts of desalted whey powder, 20 parts of skimmed milk powder, 18 parts of whey protein powder (rich in milk fat globule membrane), 2 parts of whey protein powder (rich in casein glycomacropeptide), 33 parts of galacto-oligosaccharide, 24 parts of fructo-oligosaccharide, 0.18 part of probiotics, 2.5 parts of compound vitamin and 8 parts of compound mineral.
The infant formula of this embodiment is prepared by a dry process, and mainly comprises: proportioning, preheating, homogenizing, concentrating, sterilizing, spray drying, dry-mixing and adding probiotics to obtain the finished product. Through detection, each index of the finished product meets the standard requirements of infant formula.
Example 2
This example provides a powdered infant formula of 6 to 12 months of age having a total protein content of 12.5g/100g powder and a fat content of 22.9g/100g powder; the carbohydrate content is 57.9g/100g powder, and the probiotics is 1.5X10 9 CFU/100g powder; milk fat globule membrane: casein glycomacropeptide=7:1.
The embodiment is realized by compounding the following raw materials in parts by weight:
2000 parts of raw milk, 235 parts of desalted whey powder, 239 parts of lactose, 100 parts of skimmed milk powder, 150 parts of mixed vegetable oil (containing OPO structural fat), 14 parts of whey protein powder (rich in milk fat globule membrane), 2 parts of whey protein powder (rich in casein glycomacropeptide), 0.5 part of bifidobacterium lactis, 3 parts of compound vitamin and 6 parts of compound mineral.
The infant formula of this embodiment is prepared by a dry process, and mainly comprises: proportioning, preheating, homogenizing, concentrating, sterilizing, spray drying, dry-mixing and adding probiotics to obtain the finished product. Through detection, each index of the finished product meets the standard requirements of the infant formula.
Example 3
The embodiment provides a powdered formula goat milk powder for infants of 12-36 months old, wherein the total protein content in the powdered formula is 13.8g/100g powder, and the fat content is 23.5g/100g powder; a carbohydrate content of 57.5g/100g flour; probiotics 1×10 9 CFU/100g powder. Milk fat globule membrane: casein glycomacropeptide = 6:1. the embodiment is realized by compounding the following raw materials in parts by weight:
1900 parts of raw goat milk, 325 parts of desalted whey powder, 140 parts of lactose, 140 parts of mixed vegetable oil (containing OPO structural fat), 80 parts of whey protein powder WPC, 33 parts of whey protein powder (rich in milk fat globule membrane), 12 parts of whey protein powder (rich in casein glycomacropeptide), 2 parts of galacto-oligosaccharide, 85 parts of fructo-oligosaccharide, 13 parts of probiotics, 0.33 part of probiotics, 3 parts of compound vitamin and 6 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry production process and mainly comprises the following components: proportioning, preheating, homogenizing, concentrating, sterilizing, spray drying, dry-mixing and adding probiotics to obtain the finished product. Through detection, each index of the finished product meets the standard requirement of infant formula food.
Example 4
This example provides a powdered pediatric formula of sheep milk powder, wherein the powdered formula contains total eggs17.5g/100g white matter content, 21g/100g fat content; a carbohydrate content of 50.5g/100g flour; HN019 probiotics 1×10 9 CFU/100g powder. Milk fat globule membrane: casein glycomacropeptide = 5:1.
the embodiment is realized by compounding the following raw materials in parts by weight:
430 parts of whole goat milk powder, 425 parts of desalted whey powder (derived goat milk), 4 parts of lactose, 60 parts of mixed vegetable oil (containing OPO structural fat), 80 parts of whey protein powder WPC, 10 parts of whey protein powder (rich in milk fat globule membrane), 2 parts of whey protein powder (rich in casein glycomacropeptide), 30 parts of galacto-oligosaccharide, 25 parts of fructo-oligosaccharide, 0.33 part of bifidobacterium lactis, 3 parts of compound vitamin and 6 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry production process and mainly comprises the following components: proportioning, preheating, homogenizing, concentrating, sterilizing, spray drying, dry-mixing and adding probiotics to obtain the finished product. Through detection, each index of the finished product meets the standard requirements of the prepared milk powder food.
Verification example
Efficacy experiment of milk fat globule membrane and Casein glycomacropeptide composition
Examples
1. Sample of
The Milk Fat Globule Membrane (MFGM) and Casein Glycomacropeptide (CGMP) of the research are mainly from whey powder rich in MFGM and CGMP, and the whey powder rich in the Milk Fat Globule Membrane (MFGM) has the protein content of 69-76wt%, the fat content of 16-22wt% and the phospholipid content of 6-10wt% and is prepared into the formula powder to be tested with different proportions by adjusting the addition amount of the two whey powders; in the whey protein powder rich in Casein Glycomacropeptide (CGMP), the content of CGMP is 60-80wt%, and the content of sialic acid is 4-6wt%.
According to the nutrition requirements of newborn piglets, various required nutrients are added to prepare basic formula milk powder so as to ensure the normal growth of the piglets. The specific formulation of the base formula milk powder is shown in table 1.
TABLE 1
2 prophase preparation
2.1 laboratory animals
The experiment uses a new born 2-day-old common grade male three-way hybrid piglet. The weight range of piglets is 1.3-2.0kg, and 10 piglets are taken in each experimental group, and the total weight is 80.
2.2 animal feeding conditions
The piglet feeding conditions are executed according to national standard GB 14125-2010 of the people's republic of China, and specifically comprise the following steps:
temperature: room temperature is 16-26 ℃;
humidity: relative humidity 40-70%;
illumination: artificial lighting, 12 hours of light and shade alternation;
ventilation times: more than or equal to 8 times per hour, and 100 percent of fresh air;
the feeding method comprises the following steps: the feeding times were 9am,1pm,5pm,9pm and 1am 5 times daily.
3 test design
3.1 animals into groups and feeding
2-day-old newborn male piglets are selected, and the weight of the newborn male piglets is 1.3-2.0kg, and 5-10 newborn male piglets are put into the room in batches according to the breeding condition of sows. The daily feed amount is adjusted according to the weight of the piglets in the same day. The milk is prepared with warm water (37-40 ℃) and reconstituted every 4-5 hours. Piglets were raised to day 30 post partum.
3.2 packet information
On the premise of the basic formula powder in table 1, the dosage and the proportion of MFGM and CGMP are adjusted to finally form 8 formulas, which are specifically as follows:
TABLE 2
3.3 piglet State observations and physiological indicators
The feeding, activity and rest conditions of the piglets are tracked and observed during the experiment, and the diarrhea condition of the piglets is emphasized. The fasting weight of the piglets is recorded in the morning every day, and the daily feed intake is measured and calculated. And the weight gain of piglets during the whole test period was calculated.
3.4 intestinal tissue index of piglet
On the last day of the experiment (thirty days of feeding), the acquisition of the intestinal sample of the piglet is completed, and the small intestine length, the total weight, the villus height, the crypt depth and the villus crypt ratio of the piglet are analyzed and measured.
4 test results
4.1 piglet physiological index
1) Weight index
Initial weight was recorded at the time of piglet group entry and piglet weight was recorded at fixed time daily during the test phase, following piglet weight change (see figure 1).
Analysis of the weight gain of piglets revealed no significant differences in weight gain of animals during the test period, indicating that the tested formulation met the normal growth requirements of piglets (see fig. 2).
2) Food intake
The daily feed intake of the piglets is positively correlated with the body weight, the variation trend of the daily feed intake of the piglets is consistent, and each group has no obvious difference (shown in figure 3), so that the daily feed intake of the piglets is not influenced by the tested formula.
4.2 intestinal tissue
(1) Total weight and length of small intestine
The whole small intestine of the piglet of composition 1 was selected and the length was measured with a tape measure. The weight of the small intestine is weighed by a platform scale (see fig. 4). Since the length and weight of the small intestine vary greatly among animals of different weights, the small intestine length (cm)/weight (kg) and small intestine weight (g)/weight (kg) were selected for statistical analysis. There was no significant difference in the length and weight of the small intestine for each group (fig. 5).
(2) Small intestine villus height (microns), crypt depth (microns), villus-crypt ratio
After the intestinal tissue sample was fixedly embedded, the tissue was subjected to a section staining treatment, pathological changes of the small intestine, duodenum (composition 2), jejunum (composition 1) and ileum (composition 6) were observed under a microscope, and villus length and crypt depth of the duodenum, jejunum and ileum were measured (fig. 6):
the individual groups of duodenum, jejunum and ileum were analyzed for villus length, crypt depth and villus crypt analysis for the extent of intestinal development of piglets (fig. 7, 8 and 9). The results showed no difference in duodenal villus height, crypt depth, and small intestinal villus crypt ratio between groups.
While groups 6 and 7 can significantly increase jejunal and ileal intestinal villus height and villus crypt ratio, significantly higher than control and other groups. The MFGM+CGMP composition (groups 6 and 7) was shown to promote elevation of intestinal villus height and promote intestinal maturation in piglets. And mfgm+cgmp compositions (groups 6 and 7) have a synergistic effect in promoting intestinal villi development and intestinal maturation in piglets compared to MFGM groups alone (groups 2 and 3) and CGMP alone (group 4).
The foregoing is merely a preferred embodiment of the present application and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present application, which are intended to be comprehended within the scope of the present application.

Claims (10)

1. Use of a composition for the preparation of a product for improving intestinal development; the composition comprises 1-10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in casein glycomacropeptide.
2. Use according to claim 1, characterized in that the composition comprises 5-9 parts by weight of whey protein powder enriched in milk fat globule membranes and 1 part by weight of whey protein powder enriched in casein glycomacropeptide.
3. Use according to claim 1, characterized in that the content of phospholipids in the whey protein powder enriched in milk fat globule membrane is not less than 4wt%; the content of sialic acid in the whey protein powder rich in casein glycomacropeptide is not less than 3wt%.
4. Use according to claim 1, wherein the product comprises an infant formula and/or a child formula.
5. The use according to claim 4, wherein the infant formula has a total protein content of 8g to 20g/100g, and whey protein is present in a proportion of 40% to 80% of the total protein; the fat content is 15 g-30 g/100g; the carbohydrate content is 50 g-70 g/100g;
the linoleic acid content is 2700-4500 mg/100g, and the alpha-linolenic acid content is 270-450 mg/100g.
6. The use according to claim 5, wherein the infant formula further comprises one or more of nutrients, dietary fibers, probiotics, inositol, taurine, l-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, lactoferrin, OPO, casein calcium peptide, or casein phosphopeptide.
7. The use according to claim 4, wherein the children's formula has a total protein content of more than 16.5g/100g in reduced dry matter;
the children formula food also comprises one or more of nutrients, dietary fibers, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotide, lactoferrin, OPO, casein calcium peptide or casein phosphopeptide.
8. The use according to claim 1, wherein the improvement of intestinal development comprises an increase in intestinal villus height and/or an increase in crypt depth.
9. The use of claim 8, wherein the improving intestinal development comprises increasing the chorionic villus ratio.
10. The use according to claim 8 or 9, wherein the intestine is the jejunum and/or ileum.
CN202310814187.8A 2023-07-04 2023-07-04 Application of composition in preparation of product for improving intestinal development Pending CN116711781A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310814187.8A CN116711781A (en) 2023-07-04 2023-07-04 Application of composition in preparation of product for improving intestinal development

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310814187.8A CN116711781A (en) 2023-07-04 2023-07-04 Application of composition in preparation of product for improving intestinal development

Publications (1)

Publication Number Publication Date
CN116711781A true CN116711781A (en) 2023-09-08

Family

ID=87864475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310814187.8A Pending CN116711781A (en) 2023-07-04 2023-07-04 Application of composition in preparation of product for improving intestinal development

Country Status (1)

Country Link
CN (1) CN116711781A (en)

Similar Documents

Publication Publication Date Title
Brink et al. Milk fat globule membrane: the role of its various components in infant health and development
CN111248287B (en) Application of dairy product in improving neurodevelopment
DE3856214T2 (en) Diet compositions and methods of using bile acid activated lipase
JP3195594B2 (en) A food composition containing a milk-derived phospholipid.
AU2021340764B2 (en) Infant formula milk powder rich in milk fat globule membrane protein, phospholipid and oligosaccharide, and preparation method therefor
SE1250357A1 (en) Nutritional composition with low calorie and low protein content
AU2019291666B2 (en) Use of polar lipids to treat or prevent gestational diabetes mellitus
Venkat et al. Milk polar lipids composition and functionality: A systematic review
CN112998080A (en) Infant formula milk powder added with yolk phospholipid, soybean phospholipid and milk phospholipid
RU2468610C2 (en) Composition of milk fat and milk protein preferably etherified with palmitinic acid for calcium assimilation improvement
CN113660867B (en) Nutritional composition exhibiting phase separation under gastric conditions and method of making the same
JP4034370B2 (en) Brain function improving agent and nutritional composition
CN116711781A (en) Application of composition in preparation of product for improving intestinal development
US20220386671A1 (en) Nutritional composition comprising milk and egg phospholipids
CN116649420B (en) Nutritional milk powder with effects of nourishing intelligence and promoting digestion and absorption, and its preparation method
Ivanova Investigating optimal lipid: protein profiles for infant milk formula
US20240216434A1 (en) Nutritional compositions for human consumption and methods for making same
CN115191604A (en) Nutritional composition, food containing nutritional composition and application of nutritional composition
CN117652577A (en) Infant formula milk powder capable of affecting brain hippocampus protein expression and preparation method thereof
CN118252256A (en) Composition, application thereof and food
CN117481201A (en) Formula milk powder for promoting brain development and preparation method and application thereof
Ptasińska-Marcinkiewicz COW’S MILK-PRODUCTION, CONSUMPTION AND HEALTH PROMOTING COMPOUNDS
JP2002167331A (en) Digestion and absorption accelator

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination